Author

Daniel J. Powell

University of PennsylvaniaORCID 0000-0002-5966-8908Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Daniel J. Powell1 paper · Harvard University

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:scRNA-seq· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Adam Cain ResnickiD· 1 shared Adanna Mogbo· 1 shared Alvin FarreliD· 1 shared Ammar S. NaqviiD· 1 shared Andrei Thomas‐TikhonenkoiD· 1 shared Annette CastroiD· 1 shared Berk Mankaliye· 1 shared Charles DrummeriD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam Cain ResnickORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

NRCAM variant defined by microexon skipping is a targetable cell surface proteoform in high-grade gliomas

Priyanka D. Sehgal, Ammar S. Naqvi, Makenna Higgins, Jia‐Geng Liu, Kyra Harvey, Julien Jarroux, Tae Woo Kim, Berk Mankaliye, Pamela Mishra, Grace Watterson, Justyn Fine, Jacinta Davis, Katharina E. Hayer, Annette Castro, Adanna Mogbo, , Andrei Thomas‐Tikhonenko

The paper identifies a NRCAM proteoform with skipped microexons as a targetable surface antigen in pHGG and demonstrates its utility in immunotherapy.

Cell Reports · Aug 1, 2025Peer-reviewedCancer Biology